Leqvio Real-World Response Rate: What Patients and Clinical Data Actually Show

At a glance

• Drug / inclisiran (Leqvio), a small interfering RNA that lowers LDL-C by targeting PCSK9 [3]
• Dose / 284 mg subcutaneous injection at day 1, at 3 months, then every 6 months [3]
• Who gives it / a healthcare professional, not the patient at home [3]
• ORION-10 / 1,561 adults with ASCVD; -52% vs placebo at day 510 [1]
• ORION-11 / 1,617 adults with ASCVD or risk equivalent; -50% vs placebo at day 510 [1]
• ORION-9 / 482 adults with HeFH; -47.9 point difference vs placebo [2]
• Common adverse reaction / injection site reaction 8% vs 2% on placebo [3]

What Does a Leqvio 'Response Rate' Actually Mean?

The headline figures from the ORION trials are mean percentage changes in LDL-C compared with placebo. An average 50% reduction describes the group as a whole; it does not mean every patient gets a 50% drop.

What the ORION Trials Showed

In ORION-10, 1,561 adults with ASCVD on maximally tolerated statins received inclisiran 284 mg or placebo on day 1, day 90, then every 6 months; the placebo-corrected LDL-C change at day 510 was -52% (52.3% in the paper) [1]. ORION-11 enrolled 1,617 adults with ASCVD or an ASCVD risk equivalent and found -50% (49.9% in the paper) [1]. Mean baseline LDL-C was about 105 mg/dL in both trials [1].

ORION-9 tested 482 adults with heterozygous familial hypercholesterolemia (mean baseline LDL-C 153 mg/dL) using inclisiran sodium 300 mg, equivalent to the labeled 284 mg [2][3]. At day 510, LDL-C fell 39.7% with inclisiran and rose 8.2% with placebo, a between-group difference of -47.9 percentage points [2]. In adolescents 12 to 17 with HeFH, ORION-16 found a -29% LDL-C difference at day 330 (93 on Leqvio versus 48 on placebo) [3].

How the Trial Settings Relate to Routine Use

Trial participants were taking maximally tolerated statins, and people taking PCSK9 inhibitors were excluded from ORION-10 and ORION-11 [3]. For missed doses, the label says that if a planned dose is missed by less than 3 months, give it and keep the original schedule; if missed by more than 3 months, restart with the initial, 3-month, then every-6-month schedule [3]. The label also says LDL-C can be measured as early as 30 days after the first dose, regardless of when the dose is given [3].

What the Label Says to Watch For

The label has no boxed warning; its only Warning and Precaution is hypersensitivity, including anaphylaxis and angioedema, and it advises patients to seek medical attention promptly for symptoms [3]. Prior serious hypersensitivity to inclisiran or an excipient is a contraindication [3]. In pooled adult placebo-controlled trials, injection site reactions occurred in 8% on Leqvio versus 2% on placebo, arthralgia in 5% versus 4%, and bronchitis in 4% versus 3%; adverse reactions led to discontinuation in 2.5% versus 1.9% [3].

Does Leqvio Lower Heart Attacks and Strokes?

The label says cardiovascular outcomes trials have shown that lowering LDL-C reduces major adverse cardiovascular events in adults at increased risk treated with statins or PCSK9 monoclonal antibodies added to a statin; it does not report a cardiovascular outcomes result for inclisiran itself [3]. ORION-10 and ORION-11 were not designed to show reduced cardiovascular events [1].

Frequently asked questions

›How much does Leqvio lower LDL-C?

In ORION-10 and ORION-11 the placebo-corrected reductions at day 510 were 52% and 50%. In ORION-9, LDL-C fell 39.7% on inclisiran versus a rise of 8.2% on placebo, a -47.9 point difference [1][2].

›Does Leqvio work for everyone?

The trials report average group changes, not individual responder rates, so an average of about 50% is not a certain drop for any one person [1].

›What are the common side effects of Leqvio?

In pooled adult placebo-controlled trials, injection site reactions were 8% versus 2% on placebo, arthralgia 5% versus 4%, and bronchitis 4% versus 3%. The label's only Warning and Precaution is hypersensitivity, including anaphylaxis and angioedema [3].

›Does Leqvio reduce heart attacks or strokes?

The label reports that lowering LDL-C with statins or PCSK9 monoclonal antibodies reduces major adverse cardiovascular events, but it does not report a cardiovascular outcomes result for inclisiran itself [3].

References

1. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
2. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
3. U.S. National Library of Medicine, DailyMed. LEQVIO (inclisiran) prescribing information. LEQVIO (inclisiran) label